Why the study?
Do class III antiarrhythmics offer greater efficacy and less proarrhythmia than class I agents in treating cardiac arrhythmias?
Comparison
Class III antiarrhythmics vs Conventional class I antiarrhythmics
Design
Review
Authors
Loading...
May inform selective class III development in models; leaves open clinical translation and requires trials.
Do class III antiarrhythmics offer greater efficacy and less proarrhythmia than class I agents in treating cardiac arrhythmias?
More selective class III antiarrhythmics targeting specific potassium channels may offer improved safety and efficacy over conventional class I agents by reducing nonspecific proarrhythmic effects like torsade de pointes.
Colatsky et al. (1990) studied this question.